Under construction – not a live service
Sign in
Taking people in United StatesEarly phase 1

Tests dichloroacetate effects on brain sugar use in type 1 diabetes

Tests dichloroacetate in adults with type 1 diabetes and low blood sugar awareness.

Plain-language title generated from the registry record
Registry title: Regulation of Brain Glucose Metabolism in Type 1 Diabetes

Key facts

Where
New Haven, United StatesSee the site
Phase
Early phase 1

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 55 years old?

Source: NCT05317455, who can take part

Where in United States

  • Yale New Haven HospitalNew Haven, United StatesTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Yale University
Trial code
NCT05317455
Record updated
9 June 2026
Original description
This is a prospective randomized placebo-controlled double-blind crossover pilot study determining the effect of dichloroacetate on brain function under clamped hypoglycemia in T1DM.Read full original descriptionShow less

Regulation of Brain Glucose Metabolism in Type 1 Diabetes

This is a prospective randomized placebo-controlled double-blind crossover pilot study determining the effect of dichloroacetate on brain function under clamped hypoglycemia in T1DM.

Inclusion: T1DM subjects with:; a history of severe hypoglycemia and/or hypoglycemia unawareness or; a history of severe hypoglycemia with a blood glucose <54 mg/dL, requiring the assistance of another person (with recovery after the administration of oral carbohydrate, intravenous glucose, or glucagon) or; at least 2 values <54mg/dl during 2 weeks of CGMS testing during the week prior to study.

Exclusion: Age < 18 years or >55 years; Body weight >85 kg at screening visit; BMI > 30 (female) and >30 (male) kg/m2; Untreated proliferative retinopathy; carriers of glutathione transferase Z1 (GSTZ-1) gene polymorphisms that predispose to DCA accumulation and toxicity.

ClinicalTrials.gov NCT05317455